Perspective · 10 Oct 2025
Research articlePublished 1 Dec 2023
Therapy for Obstructive Sleep Apnea Using Hypoglossal Nerve Stimulation
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Sleep apnoea affects almost one billion people worldwide. Moderate to severe forms of Obstructive Sleep Apnoea (OSA) are associated with an increased risk of cardiovascular and cerebrovascular diseases. Sleep apnoea syndromes are characterized by breathing cessation during sleep. Such hypopnea or apnoeic episodes that last for at least 10 seconds lead to generalized hypoxemia, which not only negatively affects the cardiovascular and neurological systems but also has long-term consequences, including global respiratory failure. Although these episodes do not last for more than 30-50 seconds, it is inevitable that global respiratory failure will develop. Such episodes activate the sympathetic system, creating an undesirable flight-or-fight state, which has negative effects on the sleep cycle. Repetition of these sympathetic states also contributes to nocturnal hypertension, which progresses to essential therapy-resistant hypertension. Consequently, sleep apnoea shortens the estimated average lifespan due to an increased risk of strokes and acute myocardial infarction. Despite the available therapeutic options, including positive pressure ventilation and surgeries, there are no cures or optimal therapeutic options for the prevention of complications. Therefore, the development of new therapies is essential. The current first-line therapeutic option is a Continuous Positive Airway Pressure (CPAP) machine. Although CPAP has been proven to be a successful treatment for many patients, the issue is patients’ lack of adherence to the therapy. Surgical and conservative treatment options are also available. However, the effectiveness of such therapies has not been proven to be better. A relatively new therapeutic option, Hypoglossal Nerve Stimulation (HNS), is now available. This is a minor surgical intervention in which a pacemaker is inserted to control breathing when apnoea–hypopnea episodes occur. HNS may be the next standard therapeutic option for select patients suffering from OSA. In this article, we systematically reviewed articles addressing OSA, CPAP, and HNS. We discuss the effectiveness of HNS therapy on the Apnoea–Hypopnea Index (AHI), BMI, and systolic blood pressure. We also include the advantages and disadvantages of the therapeutic options currently available for OSA treatment.
Keywords
- Obstructive Sleep Apnoea (OSA)
- Hypoglossal Nerve Stimulation (HNS)
- Continuous Positive Airway Pressure (CPAP)
- Apnoea–Hypopnea Index (AHI)
- Central Sleep Apnoea (CSA)
- Obstructive Sleep Apnoea Syndrome (OSAS)
- Two Diabetes Mellitus (T2DM)
- Acute Myocardial Infarctions (AMI)
- Body Mass Index (BMI)
- Uvulo-Palato-Pharyngoplasty (UPPP).
Subjects
Pulmonology & RespiratoryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Sleep Disorders & Therapy.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Sleep Disorders & Therapy
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Yamaguchi Mosako”
- BylineArticles whose byline prints “Kato Yamaha”

